
Local infiltration with long-acting liposome bupivacaine (Exparel) as part of a non-narcotic multimodal pain management regimen for joint replacement surgeries, meaningfully improves patient and hospital economic outcomes, according to new data presented at the 81st annual meeting of the American Academy of Orthopaedic Surgeons (AAOS).



